Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug BenlystaŽ (belimumab), approved by the U.S. Food and Drug Administration. BenlystaŽ, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues...

More...